Therefore, while the role of p38–MAPK and its effects on microglial activation need to be clarified through further research, in AD, the activation of p38–MAPK plays a crucial role in microglial inflammatory responses and disease progression, making it a promising therapeutic target. Here, MAPK1 is linked to Alzheimer disease.